For research use only. Not for therapeutic Use.
Leuprolide acetate（Cat No.:I004762）, also known as Leuprorelin, is a synthetic nonapeptide with agonistic properties towards the gonadotropin-releasing hormone receptor (GnRHR). It is widely utilized in clinical treatments for conditions such as prostate cancer, endometriosis, uterine leiomyoma (fibroids), central precocious puberty, and in vitro fertilization (IVF). By acting as a GnRHR agonist, Leuprolide acetate suppresses the production of sex hormones, effectively controlling hormone-dependent diseases and assisting in reproductive procedures. Its versatility and efficacy make it a valuable therapeutic option in various medical contexts.
| Catalog Number | I004762 |
| CAS Number | 74381-53-6 |
| Synonyms | Leuprorelin acetate;Lupron |
| Molecular Formula | C61H88N16O14 |
| Purity | 98% |
| Documentation | |
| Target | GnRH |
| Solubility | DMSO: ≥ 43.4 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide |
| InChI | InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1 |
| InChIKey | RGLRXNKKBLIBQS-XNHQSDQCSA-N |
| SMILES | CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O |
| Reference | </br>1:The impact of postnatal leuprolide acetate treatment on reproductive characteristics in a rodent model of polycystic ovary syndrome. Serrano Mujica LK, Bertolin K, Bridi A, Glanzner WG, Rissi VB, de Camargo FL, Zanella R, Prestes OD, Moresco RN, Antoniazzi AQ, Dias Gonçalves PB, Premaor MO, Comim FV.Mol Cell Endocrinol. 2017 Feb 15;442:125-133. doi: 10.1016/j.mce.2016.12.015. Epub 2016 Dec 14. PMID: 27988272 </br>2:Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate. Báez-Santos YM, Otte A, Mun EA, Soh BK, Song CG, Lee YN, Park K.Int J Pharm. 2016 Nov 30;514(1):314-321. doi: 10.1016/j.ijpharm.2016.06.138. PMID: 27863678 </br>3:Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Hoda MR, Kramer MW, Merseburger AS, Cronauer MV.Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28. Review. PMID: 27826989 </br>4:Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate. Park S, Kim DH, Kim Y, Park JH, Lee M, Song IS, Shim CK.Drug Dev Ind Pharm. 2017 Mar;43(3):441-447. doi: 10.1080/03639045.2016.1258409. Epub 2016 Nov 22. PMID: 27824264 </br>5:Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. Lee PA, Luce M, Bacher P.J Pediatr Endocrinol Metab. 2016 Nov 1;29(11):1249-1257. doi: 10.1515/jpem-2016-0026. PMID: 27740929 </br>6:Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment. Kiba A, Banno K, Yanokura M, Asada M, Nakayama Y, Aoki D, Watanabe T.J Obstet Gynaecol Res. 2016 Dec;42(12):1734-1743. doi: 10.1111/jog.13137. Epub 2016 Oct 6. PMID: 27709720 </br>7:Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, Norton M.Res Rep Urol. 2016 Aug 23;8:159-64. doi: 10.2147/RRU.S111475. eCollection 2016. PMID: 27602344 Free PMC Article</br>8:Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation. Hirota K, Doty AC, Ackermann R, Zhou J, Olsen KF, Feng MR, Wang Y, Choi S, Qu W, Schwendeman AS, Schwendeman SP.J Control Release. 2016 Dec 28;244(Pt B):302-313. doi: 10.1016/j.jconrel.2016.08.023. Epub 2016 Aug 24. PMID: 27565212 </br>9:In situ-forming PLGA implants loaded with leuprolide acetate/β-cyclodextrin complexes: mathematical modelling and degradation. Rahimi M, Mobedi H, Behnamghader A.J Microencapsul. 2016 Jun;33(4):355-64. doi: 10.1080/02652048.2016.1194905. Epub 2016 Aug 9. PMID: 27530523 </br>10:Mid-luteal phase injection of subcutaneous leuprolide acetate improves live delivered pregnancy and implantation rates in younger women undergoing in vitro fertilization-embryo transfer (IVF-ET). Check JH, Wilson C, Choe JK.Clin Exp Obstet Gynecol. 2016;43(2):173-4. PMID: 27132401 |
